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Abstract 
Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality 
worldwide. Genetic risk loci provide novel insights into disease pathogenesis. We performed a 
genome-wide association study in 35,735 cases and 222,076 controls from the UK Biobank and 
additional studies from the International COPD Genetics Consortium. We identified 82 loci with 
P-value < 5 × 10-8; 47 were previously described in association with either COPD or population-
based lung function. Of the remaining 35 novel loci, 13 were associated with lung function in 
79,055 individuals from the SpiroMeta consortium. Using gene expression and regulation data, 
we identified enrichment for loci in lung tissue, smooth muscle and several lung cell types. We 
found 14 COPD loci shared with either asthma or pulmonary fibrosis. COPD genetic risk loci 
clustered into groups of quantitative imaging features and comorbidity associations. Our analyses 
provide further support to the genetic susceptibility and heterogeneity of COPD. 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a disease of enormous and growing global 
burden1, ranked third as a global cause of death by the World Health Organization in 20162. 
Environmental risk factors, predominately cigarette smoking, account for a large fraction of 
disease risk, but there is considerable variability in COPD susceptibility among individuals with 
similar smoking exposure. Studies in families and in populations demonstrate that genetic factors 
account for a substantial fraction of disease susceptibility. Similar to other adult-onset complex 
diseases, common variants likely account for the majority of population genetic susceptibility3,4. 
Our previous efforts identified 22 genome-wide significant loci5. Expanding the number of loci 
can lead to novel insights into disease pathogenesis, not only through discovery of novel biology 
at individual loci6,7, but also across loci via identification functional links and specific cell types 
and phenotypes5. 
We performed a genome-wide association study combining previously described studies from 
the International COPD Genetics Consortium (ICGC)5 with additional subjects from the UK 
Biobank8, a population-based study of several hundred thousand subjects with lung function and 
cigarette smoking assessment. We determined, through bioinformatic and computational 
analysis, the likely set of variants, genes, cell types, and biologic pathways implicated by these 
associations. Finally, we assessed our genetic findings for relevance to COPD-specific, 
respiratory, and other phenotypes. 
 
  
Results 
Genome-wide association study of COPD 
We included a total of 257,811 individuals from 25 studies in the analysis, including studies 
from International COPD Genetics Consortium and UK Biobank (Figure 1). We defined COPD 
based on pre-bronchodilator spirometry according to modified Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria for moderate to very severe airflow limitation9, as 
done previously5. This definition resulted in 35,735 cases and 222,076 controls (Supplementary 
Table 1). We tested association of COPD and 6,224,355 variants in a meta-analysis of 25 studies 
using a fixed-effects model. We found no evidence of confounding by population substructure 
using linkage disequilibrium score regression10 (LDSC) intercept (1.0377, s.e. 0.0094). 
We identified 82 loci (defined using 2-Mb windows) at genome-wide significance (P < 5 × 10-8) 
(Figure 1 and 2; Supplementary Figures 1 and 2). Forty-seven of 82 loci were previously 
described as genome-wide significant in COPD5,11 or lung function12–20 (Supplementary Table 
2), leaving 35 novel loci (Table 1) at the time of analysis. We then sought to replicate these loci. 
Given the strong genetic correlation between population-based lung function and COPD, we 
tested the lead variant at each locus for association with forced expiratory volume in 1 s 
(FEV1)or FEV1/forced vital capacity (FVC) in 79,055 individuals from SpiroMeta
21 
(Supplementary Table 3). We identified 13 loci - C1orf87, DENND2D, DDX1, SLMAP, BTC, 
FGF18, CITED2, ITGB8, STN1, ARNTL, SERP2, DTWD1, and ADAMTSL3 – that replicated 
using a Bonferroni correction for a one-sided P < 0.05/35; Table 1). Although not meeting the 
strict Bonferroni threshold, additional 14 novel loci were nominally significant in SpiroMeta 
(consistent direction of effect and one-sided P < 0.05): ASAP2, EML4, VGLL4, ADCY5, HSPA4, 
CCDC69, RREB1, ID4, IER3, RFX6, MFHAS1, COL15A1, TEPP, and THRA (Table 1), and all 
82 loci showed consistent direction of effect with either FEV1 or FEV1/FVC ratio in SpiroMeta 
(Table 1 and Error! Reference source not found.). We note that 9 of our 35 novel loci were 
recently described in a contemporaneous analysis of lung function in UK Biobank21. None of the 
novel loci appeared to be explained by cigarette smoking, and variant effect sizes in ever- and 
never-smokers and including and excluding self-reported asthmatics were similar 
(Supplementary Note). In addition, we found no significant differences in variant effects by sex 
(Supplementary Note). Including all 82 genome-wide significant variants, we explain up to 
7.0% of the phenotypic variance in liability scale, using a 10% prevalence of COPD, 
acknowledging that these effects are likely overestimated in the discovery sample. This 
represents up to a 48% increase in COPD phenotypic variance explained by genetic loci 
compared to the 4.7% explained by 22 loci reported in a recent GWAS of COPD5. 
Identification of secondary association signals 
We used approximate conditional and joint analysis22 to find secondary signals at each of the 82 
genome-wide significant loci. We found 82 secondary signals at 50 loci, resulting in a total of 
164 independent associations in 82 loci (Supplementary Table 4). Of 50 loci containing 
secondary associations, 33 were at loci previously described for COPD or lung function, and six 
at Bonferroni-replicated novel loci. Of 82 secondary associations, 20 reached genome-wide 
significance (P < 5 × 10-8) (Supplementary Table 4). Of 61 novel (not previously described in 
COPD or lung function) independent associations, 21 reached a region-wise Bonferroni-
corrected threshold (one-sided P < 0.05/novel independent association(s) in each locus) in 
unconditioned associations from SpiroMeta (Methods and Supplementary Table 4).  
  
Tissue and specific cell types 
In determining the tissue in which COPD genetic variants function to increase COPD risk, lung 
is the obvious tissue to consider.  However, COPD is a systemic disease23,24 and within the lung 
the cell-types collectively contributing to disease pathogenesis are largely unknown. 
Furthermore, available databases include cell types relevant to lung (e.g. smooth muscle) but 
from other organs (e.g. the gastrointestinal tract). To identify putative causal tissues and cell 
types, we assessed the heritability enrichment in integrated genome annotations at the single 
tissue level25 and tissue-specific epigenomic marks26. Lung tissue showed the most significant 
enrichment (enrichment = 9.25, P = 1.36 × 10-9), as previously described, though significant 
enrichment was also seen in heart (enrichment = 6.85, P = 3.83 × 10-8) and the gastrointestinal 
(GI) tract (enrichment = 5.53, P = 6.45 × 10-11). In an analysis of enriched epigenomic marks, the 
most significant enrichment was in fetal lung and GI smooth muscle DNase hypersensitivity sites 
(DHS) (P = 6.75 × 10-8) and H3K4me1 (P = 7.31 × 10-7) (Supplementary Table 5). To identify 
the source of association within lung tissue, we tested for heritability enrichment using single-
cell chromatin accessibility27 (ATAC-Seq) and gene expression (RNA-Seq) from human28,29 and 
murine30 lung (Supplementary Table 5). Using LD score regression in murine ATAC-Seq data, 
we found enrichment of chromatin accessibility in several cell types, including endothelial cells 
(most significant), type 1, and type 2 alveolar cells (the latter among the highest fold-enrichment 
[Supplementary Table 5a]). Results using LD score regression31 or SNPsea32 on single-cell 
RNA-Seq varied, with nominal P-values for genes expressed in type 2 alveolar cells, basal-like 
cells, club cells, fibroblasts and smooth muscle cells (Supplementary Tables 5b,c). 
 
Fine-mapping of associated loci 
To identify the most likely causal variants at each locus, we performed fine mapping using 
Bayesian credible sets33. Including 160 potential primary and secondary association signals 
(excluding four variants in the major histocompatibility complex [MHC] region), 61 independent 
signals had a 99% credible set with fewer than 50 variants; 34 signals had credible sets with 
fewer than 20 variants (Supplementary Figure 3). Eighteen loci had a single variant with a 
posterior probability of driving association (PPA) greater than 60% including the NPNT (4q24) 
locus, where the association could be fine-mapped to a single intronic variant, rs34712979 
(NC_000004.11:g.106819053G>A, see Supplementary Note and Supplementary Table 6). 
Most sets included variants that overlapped genic enhancers of lung-related cell types (e.g., fetal 
lung fibroblasts, fetal lung, and adult lung fibroblasts) and were predicted to alter transcription 
binding motifs (Supplementary Table 6). Of 61 credible sets with fewer than 50 variants, eight 
sets contained at least one deleterious variant. These deleterious variants included 1) missense 
variants affecting TNS1, RIN3, ADGRG6, ADAM19, ATP13A2, BTC, and CRLF3; and 2) a splice 
donor variant affecting a lincRNA - AP003059.2. 
Candidate target genes 
In most cases, the closest gene to a lead SNP will not be the gene most likely to be the causal or 
effector gene of disease-associated variants34–36. Thus, to identify the potential effector (‘target’) 
genes underlying these genetic associations, we integrated additional molecular information 
including gene expression, gene regulation (open chromatin and methylation data), chromatin 
interaction, co-regulation of gene expression with gene sets, and coding variant data (Methods 
and Figure 3). 
  
At 82 loci, 472 genes within +/- 1 Mb of top associated variants were implicated by analysis of 
least one dataset; 106 genes were implicated by lung gene expression37,38, and an additional 50 
genes by >= 2 other datasets (methylation39, chromatin interaction40, open chromatin regions41, 
similarity in gene sets42 or deleterious coding variants43 [Figure 3]), for a total of 156 genes 
meeting more stringent criteria. Excluding loci in the MHC region, the median number of 
potentially implicated genes per locus was four, with a maximum of 17 genes (7q22.1 and 
17q21.1). The median distance of implicated genes to top associated variants was 346 Kb. 
Among 82 loci, 60 (73%) included the nearest gene. We identified 20 genes with supportive 
evidence from exome sequencing data. Two genes (ADAM19 and ADAMTSL3) were implicated 
by five datasets (Figure 3) and another two (EML4 and RIN3) were implicated by four datasets. 
A summary of all genes implicated using these approaches is included in Supplementary Table 
7.  
Associated pathways 
To gain further functional insight of associated genetic loci, we performed gene-set enrichment 
analysis using DEPICT42. Among 165 enriched gene sets at false discovery rate (FDR) < 5%, 
44% of them were related to the developmental process term, with nominal P for lung 
development of 1.02 × 10-6; significant sub-terms included lung alveolus development (P = 
0.0003) and lung morphogenesis (P = 0.0005). We also found enrichment of extracellular 
matrix-related pathways including laminin binding, integrin binding, mesenchyme development, 
cell-matrix adhesion, and actin filament bundles. Additional pathways of note included histone 
deacetylase binding, the Wnt receptor signaling pathway, SMAD binding, the MAPK cascade, 
and the transmembrane receptor protein serine/threonine kinase signaling pathway. Full 
enrichment analysis results including the top genes for each DEPICT gene set are shown in 
Supplementary Table 8. 
Identification of drug targets 
GWAS is also useful for identifying drug targets either at the individual gene18,44,45 or genome-
wide level46,47. Of 482 candidate target genes, 60 genes could be targeted by at least one 
approved or in-development drug48, totaling 428 drugs with 144 different modes of action 
(Supplementary Table 9). Druggable targets at novel loci for COPD and lung function included 
ABHD6, CDKL2, GSTO2, KCNC4, PDHB, SLK, and TRPM7. We also identified drugs for 
repurposing in COPD using transcriptome-wide associations and drug-induced gene expression 
signatures49 (Supplementary Note).  
Phenotypic effects of COPD-associated variants 
To characterize the phenotypic effects of 82 genome-wide significant loci, we performed a 
phenome-wide association analysis within the deeply phenotyped COPDGene study (Methods). 
We assessed for common patterns of phenotype associations for the 82 loci by using hierarchical 
clustering across scaled Z scores of phenotype-variant associations. We identified two clusters of 
variants differentially associated with two sets of phenotypes (Supplementary Figure 4). As 
these two variant-phenotype clusters appeared to be driven by computed tomography (CT) 
imaging features, we repeated variant clustering limited to quantitative computed tomography 
imaging features. We again found two clusters of variants, differentiated by association with 
quantitative emphysema, emphysema distribution, gas trapping, and airway phenotypes (Figure 
4a). Additionally, we evaluated the association of the 82 genome-wide significant variants in a 
prior GWAS of emphysema and airway quantitative computed tomography features50 
(Supplementary Table 10). 
  
We also examined all genome-wide significant loci in the NHGRI-EBI GWAS Catalog51 
(Supplementary Figure 5, Supplementary Table 11) and looked for trait-associated variants in 
linkage disequilibrium (r2 > 0.2) with our lead COPD-associated variants. Many variants were 
associated with anthropometric measures including height and body mass index (BMI), 
measurements on blood cells (red and white cells), and cancers. COPD is well known to have 
many common comorbidities, such as coronary artery disease (CAD), type 2 diabetes mellitus 
(T2D), osteoporosis, and lung cancer. Of these diseases and 13 additional traits, we confirmed 
previously reported overall genetic correlation (using linkage disequilibrium score regression52) 
of COPD with lung function, asthma, and height, and found evidence of modest correlation 
between COPD and lung cancer (Supplementary Note). However, at individual loci, and using 
more stringent linkage disequilibrium (r2 > 0.6), we found evidence of shared risk factors for 
these comorbid diseases and COPD including a genome-wide significant variant near PABPC4 
associated with T2D, four variants with CAD (near CFDP1, DMWD, STN1, and TNS1), and a 
variant near SPPL2C with bone density (Figure 4b).  
Overlapping loci with asthma and pulmonary fibrosis 
Based on our previous identification of genetic overlap of COPD with asthma, and COPD with 
pulmonary fibrosis, we examined loci for specific overlap with these two diseases. In asthma, we 
noted an r2 > 0.2 with one of our variants and previously reported variants at ID2, ZBTB38, 
C5orf56, MICA, AGER, HLA-DQB1, ITGB8, CLEC16A, and THRA. In pulmonary fibrosis, in 
addition to our previously described overlap at FAM13A, DSP, and 17q21, we noted overlapping 
associations at ZKSCAN1 and STN1 (Supplementary Table 12). To more closely examine 
overlap, we applied a Bayesian method (gwas-pw53) of COPD associations from our current 
GWAS with previous GWASs of asthma (limited to those of European ancestry) and pulmonary 
fibrosis54,55. To mitigate the results of including asthma among our COPD cases, we performed 
analysis for overlap with asthma removing self-reported asthmatics from UK Biobank for this 
analysis (Methods). We identified 14 shared genome segments (posterior probability > 70%), 9 
with asthma and 5 with pulmonary fibrosis (Figure 4c, Supplementary Table 13). In addition to 
the three segments shared with pulmonary fibrosis identified in the previous study5 (FAM13A, 
DSP, and the 17q21 locus – here nearest CRHR1), we identified two new segments including 
loci near ZKSCAN1 and STN1 (formerly known as OBFC1).  Shared variants between COPD 
and pulmonary fibrosis all had an opposite effect (i.e., increasing risk for COPD but protective 
for pulmonary fibrosis). In asthma, we identified five shared segments in the 6p21-22 regions, as 
well as ADAM19, ARMC2, ELAVL2, and STAT6.  With the exception of STAT6, overlapping 
variants showed the same direction of effect. 
 
Discussion 
Genetic factors play an important role in COPD susceptibility. We examined genetic risk of 
COPD in a genome-wide association study of 35,735 cases and 222,076 controls. We identified 
82 genome-wide significant loci for COPD, of which 47 were previously identified in genome-
wide association studies of COPD or population-based lung function. Of 35 loci not previously 
described at the time of analysis, 13 replicated in an independent study of population-based lung 
function. We used several data sources to attempt to assign causal genes at each locus, 
identifying 156 genes at 82 loci that were supported by either gene expression or a combination 
of at least 2 other data sources. Our results identify specific genes, cell types, and biologic 
  
pathways for targeted study and also suggest a genetic basis for the clinical heterogeneity seen in 
COPD. 
Our study supports the role of early life events in the risk of COPD. Gene set enrichment 
analysis identified developmental pathways both specific to the lung (e.g., lung morphogenesis 
and lung alveolar development) and related to the lung (e.g., the canonical Wnt receptor56,57, the 
MAPK/ERK, and the nerve growth factor receptor signaling pathways). We also confirmed 
enrichment of heritability in epigenomic marks of fetal lung. Our findings are consistent with 
epidemiologic studies demonstrating that a substantial portion of the risk of COPD may develop 
in early life: genetic variants may set initial lung function58 and patterns of growth58–60. While 
further work will be needed to confirm the causal variants and genes affected by our variants, 
testing the role of these genes in lung development-relevant murine or ex-vivo models – for 
example, determining whether the perturbation of these genes changes proliferation and 
differentiation of lung epithelial progenitors in induced pluripotent cell-derived lung alveolar 
type 2 cells44 – could provide experimental evidence of the role of these genes in early life 
susceptibility.  Ultimately, the goal of this work would be to identify targets for or subsets of 
high risk individuals early in the disease course, or molecular candidates that may affect lung 
repair and regeneration61. 
Apart from genes related to lung development, our analyses highlighted several genes and 
pathways already of interest in COPD therapy (e.g. CHRM3 / acetylcholine receptor inhibitors, 
the MAPK pathway) – supporting the role of genetic analyses in finding therapeutic targets18,62 – 
and newer genes that could inform future functional studies. We identified interleukin 17 
receptor D (IL17RD), as a potential effector gene at the 3p14 locus. Numerous studies have 
examined the role of IL-17A in COPD63, and IL17RD can differentially regulate pathways 
employed by IL-17A64 . Chitinase acidic (CHIA) at 1p13.3, which encodes a protein that 
degrades chitin65, exhibits lung-specific expression66,67. CHIA variants have been associated with 
FEV1
68, asthma69–72, and acid mammalian chitinase activity71,73. We identified several potential 
effector genes related to extracellular matrix, cell adhesion, cell-cell interactions, and elastin-
associated microfibrils74–76, some of which have been previously identified in studies of lung 
function15. These include integrin family members that mediate cell-matrix communication (e.g., 
ITGA1, ITGA2, ITGA877–79), an integrin ligand encoding gene (NPNT80), and genes encoding 
matrix proteins (e.g., MFAP2 and ADAMTSL3). ADAMTSL3 plays a role in cell-matrix 
interactions related to the assembly of fibrillin and microfibril biogenesis81–83 and of our 
candidate effector genes was supported by the greatest number of bioinformatic analyses. 
Recombinant forms of other ADAMTS-like proteins demonstrate experimental evidence of 
promoting and enhancing fibrillin and microfibril deposition and assembly84,85.  ADAMTSL3 may 
play a role in preventing emphysematous destruction of lung tissue by ADAMTS in COPD. 
In addition to identifying the effector gene, knowing the effector cell type is critical for 
functional studies. We identified an overall enrichment of epigenomic marks in lung tissue and 
smooth muscle (also identified in studies of lung function16). This latter association was found in 
gastrointestinal tissue cell types; respiratory smooth muscle is absent in the analyzed datasets. 
We also performed analyses of single-cell data in an attempt to identify the specific lung cell 
types in which our top variants are potentially functioning. We found evidence for enrichment of 
several cell types, including but not limited to endothelial cells, alveolar type 2 cells, and basal-
like cells. Each of these cell types has been postulated to have a role in the development of 
COPD86–88, and our data are consistent with the likely heterogeneity of lung cell types 
contributing to COPD susceptibility. The lung comprises at least 40 different resident cell 
  
types89, most of which are not distinctly represented in these datasets. Thus, while our findings 
support the investigation of specific cell types for further functional studies, they also highlight 
the need for profiling of lung-relevant cell types and loci-specific analyses. 
Characterization of functional variant effects could lead to better disease subtyping and more 
targeted therapy for COPD. Cluster analysis on hundreds of COPD-associated features in the 
more extensively phenotyped COPDGene cohort showed heterogeneous effects of genetic 
variants on COPD-related phenotypes, including computed tomography (CT) measurements of 
airway abnormalities and  emphysema – well-described sources of heterogeneity in COPD90–92. 
Analyzing hundreds of diseases/traits in GWAS Catalog, we identified overlapping associations 
with various diseases/traits in multiple organ systems, comorbidities such as coronary artery 
disease, bone mineral density, and type 2 diabetes mellitus (T2D). The COPD-associated 
PABPC4 locus was associated with T2D93 and C-reactive protein (CRP) level94. Although a 
causal gene in this locus and its contribution to COPD is unknown, its association with T2D may 
suggest a shared disease pathway and drug targets. Together, the identification of variable COPD 
risk loci associations with sub-phenotypes and other diseases95,96 may have potential for more 
nuanced approaches to therapy for COPD. Overall, our phenotype, gene, and pathway analyses 
illustrate the utility of both searching for enrichment of genetic signals overall, and performing a 
more detailed identification of the effects of individual variants or groups of variants. 
We performed additional specific analysis in two diseases that overlap with COPD, asthma and 
pulmonary fibrosis. While a genome-wide genetic correlation of COPD and asthma has been 
previously described5, our analysis is the first to identify specific shared genetic segments 
between asthma and COPD. While the effects at most of these shared segments were concordant 
in direction, one of the segments of particular interest was near STAT6, which had opposite 
directions of effect in the two diseases. STAT6 plays a role in T helper (Th) type 2-dependent 
inflammation, and is activated by interleukin-4 and interleukin-13 (IL-4 and IL-13)97. IL-13, in 
turn, has been found to be increased in asthmatic airways98 but decreased in severe 
emphysema99. In pulmonary fibrosis, variants at all overlapping loci have an opposite direction 
of effect compared to COPD5. These effects raise the possibility that specific therapies for one 
disease could increase the risk of the other disease, which may be worth evaluating in treatment 
trials. The reasons why genetic effects are divergent between COPD and fibrosis are unclear, but 
these identified opposite effects could point to molecular switches that influence why some 
smokers develop emphysema while others develop pulmonary fibrosis. While pulmonary fibrosis 
is an uncommon disease and specifically excluded in several of our COPD case-control cohorts, 
interstitial lung abnormalities are increasingly being recognized as a potential precursor to 
fibrosis, and an inverse relationship between these abnormalities and emphysema has been 
previously identified100. Mechanistically, some have hypothesized that the divergent 
derangement of Wnt and Notch signaling pathways101 and mesenchymal cell fate102 may be 
responsible for the distinct development of these two diseases. We also describe an overlapping 
region at the STN1 (previously known as OBFC1) locus. STN1 plays a role in telomere 
maintenance103; shortened telomeres have been observed in both COPD and idiopathic 
pulmonary fibrosis (IPF)104,105, and rare genetic variants in the telomerase pathway have been 
implicated in both pulmonary fibrosis and emphysema – albeit with concordant effects on either 
disease106.  
While our study a large genome-wide association study of COPD, individuals meeting our 
criteria for COPD in the UK Biobank may be different from other studies, especially for smoking 
history. We used the same definition of COPD as in our prior analysis5, which included non-
  
smokers. Our use of pre-bronchodilator spirometry to define COPD (allowing us to maximize 
sample size) as well as population-based lung function for replication could bias our findings 
against variants that are only associated with more severe forms of COPD. We did not exclude 
other causes of airway obstruction such as asthma, noting that asthma frequently overlaps with, 
and is misdiagnosed in COPD107. We performed several additional analyses to determine 
whether our results were driven by, or markedly different, by smoking status, asthma, or use of 
pre- instead of post-bronchodilator spirometry to define COPD. The results of these additional 
analyses did not indicate a substantial impact of these factors on our overall findings, and 
together with prior analyses5,16, suggest that bias due to these factors is likely small. However, 
our study was not designed to identify differences between subgroups, and we cannot rule out a 
role for studying more severe disease or disease subtypes. We note that the alpha-1 antitrypsin 
locus (SERPINA1) was identified as genome-wide significant in smaller studies of emphysema 
and in smokers with severe COPD108. In the current study, the association of the PiZ allele 
(NC_000014.8:g.94844947C>T, rs28929470) had P = 2.2 × 10-5 using moderate-to-severe cases 
(FEV1 < 80% predicted), and a smaller P-value (1.4 × 10
-6) in severe cases (FEV1 < 50% 
predicted) despite a smaller sample size, a phenomenon we have previously described11. Thus, 
despite the strong overlap of COPD with quantitative spirometry, new loci may be identified 
through studies of sufficiently large subsets of COPD patients and with more specific and 
homogeneous COPD phenotypes. Given suggestive evidence for replication using a related (but 
not identical) phenotype for additional novel loci beyond the 13 meeting a Bonferroni-corrected 
threshold for significance, we chose to include all loci significant in discovery in subsequent 
analyses, recognizing that we likely included some false positive associations. Our study focused 
on relatively common variants, predominantly in individuals of European ancestry; more detailed 
studies of rare variants, the human leukocyte antigen (HLA) regions, and other ethnicities are 
warranted, but broader multi-ethnic analyses are limited by the number of cases in currently 
available cohorts. Although COPD sex differences have been reported109, we did not identify 
significant sex-specific differences in effect sizes of the 82 top variants. Future studies including 
more subjects and methodological advances may be needed to elucidate this effect.  
The global burden of COPD is increasing. Our work finds a substantial number of new loci for 
COPD and uses multiple lines of supportive evidence to identify potential genes and pathways 
for both existing and novel loci. Further investigation of the genetic overlap of COPD with other 
respiratory diseases and the phenotypic effects of top loci finds new shared loci for asthma and 
idiopathic pulmonary fibrosis and suggests heterogeneity across COPD-associated loci. 
Together, these insights provide multiple new avenues for investigation of the underlying 
biology and the potential therapeutics in this deadly disease.  
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Figure legends 
Figure 1 Study design 
COPD, chronic obstructive pulmonary disease; FEV1, force expiratory volume in one second; 
FVC, forced vital capacity. ARIC, Atherosclerosis Risk in Communities. 
 
Figure 2 Manhattan plot 
P-values are two-sided based on Wald statistics (35,735 cases and 222,076 controls) without 
multiple comparison adjustment. Loci are labeled with the closest gene to the lead variant. 
Figure 3 Identification of target genes 
(a) Overview of datasets used to identify target genes at genome-wide significant loci (b) 
Regional association plots at ADAMTSL3 locus showing GWAS (top), chromatin interaction in 
lung tissue (middle) and expression quantitative trait loci (bottom). GWAS P-values are two-
sided based on Wald statistics (35,735 cases and 222,076 controls). Expression quantitative trait 
loci (eQTL) P-values are two-sided based on t statistics (1,038 samples). P-values for Hi-C data 
were calculated using binomial distribution from spline-fitted and outlier-filtered distribution of 
contacts. All P-values were not adjusted for multiple comparison. GREx, gene-based association 
using gene expression; mQTL, colocalization with methylation quantitative trait loci; Cod., 
significant single variant or gene-based association tests for deleterious coding variants from 
exome data; Hi-C, significant chromatin interaction identified in human lung or the IMR90 cell 
line; DHS, overlap with DNase hypersensitivity sites; GSet, prioritized genes from DEPICT. 
Figure 4 Effects on COPD-related and other phenotypes 
(a) Heatmap of scaled computed tomography (CT) quantitative imaging associations with the 34 
genome-wide significant variants (known and replicated novel associations) with at least 
nominal (P < 0.05) association with any CT imaging feature in COPDGene non-Hispanic white 
participants. Cluster 1 variants are more associated with airway imaging features and Cluster 2 
variants are more associated with emphysema imaging features. Variants are referred to by the 
closest gene. (b) Overlap of genome-wide significant loci of COPD and select traits from GWAS 
Catalog (c) Genome-wide overlapping results between COPD with pulmonary fibrosis (left) and 
asthma (right). PRM emphysema, emphysema quantified by parametric response mapping; UL, 
upper lobe of the lung; LL, lower lobe of the lung; Pi10, airway wall thickness calculated from 
regressing the square root of the airway wall area with the airway internal perimeter. CAD, 
coronary artery disease; BMD, bone mineral density.
  
Table 1 Meta-analysis results showing 35 loci novel for COPD and lung function 
rsID HGVS name 
Closest 
gene 
Locus 
Risk/alt. 
allele 
Risk allele 
frequency 
UK Biobank ICGC Cohorts Overall meta-analysis SpiroMeta FEV1 SpiroMeta FEV1/FVC 
OR 95% CI P value OR 95% CI P value OR 95% CI P value Beta P value Beta P value 
rs72673419 NC_000001.10:g.60913143C>T C1orf87 1p32.1 T/C 0.05 1.13 1.07-1.18 2.0E-06 1.19 1.08-1.31 2.9E-04 1.14 1.09-1.19 4.0E-09 -0.02 1.3E-01 -0.05 3.0E-04 
rs629619 
NC_000001.10:g.111738108C>T 
DENND2D 1p13.3 T/C 0.20 1.08 1.05-1.11 7.5E-08 1.10 1.04-1.16 8.2E-04 1.08 1.06-1.11 2.9E-10 -0.01 4.6E-01 -0.02 9.3E-04 
rs10929386 
NC_000002.11:g.15906179C>T 
DDX1 2p24.3 C/T 0.49 1.06 1.03-1.08 1.2E-06 1.07 1.03-1.12 1.8E-03 1.06 1.04-1.08 9.1E-09 -0.02 3.1E-06 -0.02 7.1E-06 
rs62259026 
NC_000003.11:g.57746515C>T 
SLMAP 3p14.3 C/T 0.75 1.07 1.04-1.09 1.8E-06 1.07 1.02-1.12 3.8E-03 1.07 1.04-1.09 2.4E-08 -0.03 3.3E-05 -0.01 6.4E-02 
rs4585380 
NC_000004.11:g.75673363G>A 
BTC 4q13.3 G/A 0.74 1.07 1.04-1.10 1.2E-07 1.06 1.02-1.11 8.1E-03 1.07 1.05-1.09 3.4E-09 -0.02 3.7E-04 -0.02 1.3E-03 
rs12519165 
NC_000005.9:g.170901586A>T 
FGF18 5q35.1 A/T 0.38 1.08 1.05-1.10 2.7E-10 1.02 0.97-1.08 4.0E-01 1.07 1.05-1.09 1.1E-09 -0.02 6.5E-03 -0.03 2.4E-07 
rs646695 
NC_000006.11:g.140280398T>C 
CITED2 6q24.1 C/T 0.24 1.07 1.05-1.10 3.0E-08 1.09 1.04-1.14 3.4E-04 1.08 1.05-1.10 4.6E-11 -0.02 5.6E-04 0.00 7.5E-01 
rs2040732 
NC_000007.13:g.20418134C>T 
ITGB8 7p21.1 C/T 0.58 1.07 1.05-1.09 5.2E-09 1.03 0.99-1.07 1.7E-01 1.06 1.04-1.08 6.9E-09 -0.02 1.8E-03 -0.01 1.0E-02 
rs1570221 
NC_000010.10:g.105656874G>A 
STN1 10q24.33 A/G 0.35 1.06 1.03-1.08 3.5E-06 1.07 1.03-1.12 1.4E-03 1.06 1.04-1.08 2.2E-08 -0.02 9.5E-04 -0.01 3.9E-02 
rs4757118 
NC_000011.9:g.13171236C>T 
ARNTL 11p15.2 T/C 0.54 1.07 1.04-1.09 1.1E-08 1.04 1.00-1.08 7.3E-02 1.06 1.04-1.08 3.8E-09 -0.01 2.8E-01 -0.02 2.2E-03 
rs9525927 
NC_000013.10:g.44842503G>A 
SERP2 13q14.11 G/A 0.19 1.07 1.04-1.10 2.9E-06 1.10 1.05-1.16 1.4E-04 1.08 1.05-1.10 2.8E-09 -0.02 2.2E-02 -0.02 2.2E-03 
rs72731149 
NC_000015.9:g.49984710G>C 
DTWD1 15q21.2 G/C 0.91 1.12 1.07-1.17 8.9E-07 1.12 1.04-1.20 2.6E-03 1.12 1.08-1.16 8.3E-09 -0.05 7.9E-07 -0.03 9.0E-04 
rs10152300 
NC_000015.9:g.84392907G>A 
ADAMTSL3 15q25.2 G/A 0.23 1.09 1.06-1.11 2.4E-10 1.08 1.02-1.13 4.7E-03 1.08 1.06-1.11 4.2E-12 -0.01 6.4E-02 -0.02 1.5E-03 
rs955277 
NC_000002.11:g.9290357C>T 
ASAP2 2p25.1 T/C 0.61 1.08 1.05-1.10 2.7E-10 1.04 0.99-1.08 8.6E-02 1.07 1.05-1.09 1.9E-10 0.00 9.6E-01 -0.01 3.3E-02 
rs12466981 
NC_000002.11:g.42433247C>T 
EML4 2p21 C/T 0.73 1.06 1.03-1.08 8.1E-06 1.08 1.03-1.13 1.2E-03 1.06 1.04-1.09 4.9E-08 -0.01 4.4E-02 -0.01 6.4E-02 
rs2442776 
NC_000003.11:g.11640601G>A 
VGLL4 3p25.3 G/A 0.15 1.09 1.06-1.13 5.7E-08 1.10 1.04-1.16 8.9E-04 1.09 1.06-1.12 2.0E-10 -0.01 6.4E-02 -0.01 1.3E-01 
rs4093840 
NC_000003.11:g.123077042T>A 
ADCY5 3q21.1 A/T 0.47 1.07 1.05-1.09 1.6E-09 1.04 1.00-1.09 4.8E-02 1.06 1.04-1.08 3.9E-10 -0.01 8.5E-02 -0.00 3.8E-01 
rs62375246 
NC_000005.9:g.132439010T>A 
HSPA4 5q31.1 A/T 0.26 1.08 1.05-1.10 9.6E-09 1.03 0.98-1.08 2.7E-01 1.06 1.04-1.09 2.2E-08 -0.02 1.3E-02 -0.01 2.2E-01 
rs979453 
NC_000005.9:g.150595073A>G 
CCDC69 5q33.1 G/A 0.34 1.07 1.05-1.10 1.6E-09 1.02 0.97-1.06 5.1E-01 1.06 1.04-1.08 1.4E-08 -0.01 7.2E-02 -0.00 6.4E-01 
rs1334576 
NC_000006.11:g.7211818G>A 
RREB1 6p24.3 A/G 0.42 1.07 1.05-1.09 4.2E-09 1.02 0.99-1.06 2.2E-01 1.06 1.04-1.08 1.2E-08 0.00 6.9E-01 -0.01 2.9E-02 
rs9350191 
NC_000006.11:g.19842661C>T 
ID4 6p22.3 T/C 0.85 1.11 1.08-1.15 6.2E-12 1.14 1.05-1.23 1.9E-03 1.12 1.09-1.15 5.1E-14 -0.02 4.9E-02 -0.01 1.5E-01 
rs2284174 
NC_000006.11:g.30713580T>C 
IER3 6p21.33 C/T 0.22 1.12 1.10-1.15 3.4E-19 1.12 1.05-1.21 1.5E-03 1.12 1.10-1.15 2.1E-21 -0.01 5.2E-02 -0.02 3.0E-02 
rs674621 
NC_000006.11:g.117257018T>C 
RFX6 6q22.1 C/T 0.32 1.06 1.03-1.08 1.3E-06 1.07 1.03-1.12 1.4E-03 1.06 1.04-1.08 7.6E-09 -0.01 3.6E-02 -0.01 6.9E-02 
rs9329170 
NC_000008.10:g.8697658C>G 
MFHAS1 8p23.1 C/G 0.86 1.10 1.06-1.14 2.0E-08 1.09 1.03-1.15 4.9E-03 1.10 1.07-1.13 3.6E-10 -0.02 4.6E-02 -0.01 6.5E-02 
rs10760580 
NC_000009.11:g.101661650G>A 
COL15A1 9q22.33 G/A 0.71 1.08 1.06-1.11 1.6E-10 1.04 0.99-1.09 1.1E-01 1.07 1.05-1.10 1.2E-10 -0.02 1.5E-02 -0.02 1.4E-02 
rs8044657 
NC_000016.9:g.58022625G>A 
TEPP 16q21 G/A 0.90 1.12 1.07-1.16 1.7E-07 1.09 1.01-1.17 1.8E-02 1.11 1.07-1.15 1.1E-08 -0.02 9.9E-02 -0.02 2.8E-02 
rs62065216 
NC_000017.10:g.38218773G>A 
THRA 17q21.1 A/G 0.42 1.06 1.04-1.09 1.2E-07 1.06 1.01-1.10 2.2E-02 1.06 1.04-1.08 8.1E-09 -0.01 7.8E-02 -0.00 8.0E-01 
rs4660861 
NC_000001.10:g.45946636G>T 
TESK2 1p34.1 G/T 0.57 1.05 1.03-1.08 7.2E-06 1.07 1.03-1.12 1.2E-03 1.06 1.04-1.08 4.4E-08 -0.01 3.0E-01 -0.00 4.1E-01 
rs7650602 
NC_000003.11:g.141147414T>C 
ZBTB38 3q23 C/T 0.45 1.07 1.04-1.09 6.7E-09 1.01 0.97-1.06 5.1E-01 1.06 1.04-1.08 4.9E-08 0.00 8.4E-01 -0.01 3.2E-01 
rs34651 
NC_000005.9:g.72144005C>T 
TNPO1 5q13.2 C/T 0.08 1.10 1.06-1.15 7.5E-07 1.12 1.02-1.22 1.2E-02 1.11 1.07-1.15 3.0E-08 -0.00 7.6E-01 0.00 7.5E-01 
rs798565 
NC_000007.13:g.2752152G>A 
AMZ1 7p22.3 G/A 0.71 1.09 1.06-1.11 2.8E-11 1.00 0.95-1.05 8.8E-01 1.07 1.04-1.09 3.9E-09 -0.01 1.2E-01 -0.00 6.1E-01 
  
rsID HGVS name 
Closest 
gene 
Locus 
Risk/alt. 
allele 
Risk allele 
frequency 
UK Biobank ICGC Cohorts Overall meta-analysis SpiroMeta FEV1 SpiroMeta FEV1/FVC 
OR 95% CI P value OR 95% CI P value OR 95% CI P value Beta P value Beta P value 
rs7866939 
NC_000009.11:g.85126163T>C 
RASEF 9q21.32 C/T 0.33 1.06 1.03-1.08 1.3E-06 1.07 1.02-1.12 3.8E-03 1.06 1.04-1.08 1.7E-08 -0.01 2.5E-01 -0.01 1.1E-01 
rs7958945 
NC_000012.11:g.115947901A>G 
MED13L 12q24.21 G/A 0.36 1.06 1.04-1.09 1.0E-07 1.07 1.02-1.11 2.8E-03 1.06 1.04-1.09 1.0E-09 -0.01 1.5E-01 -0.00 6.2E-01 
rs72626215 
NC_000019.9:g.46294136G>A 
DMWD 19q13.32 G/A 0.73 1.06 1.04-1.09 1.7E-06 1.11 1.05-1.17 7.3E-05 1.07 1.05-1.10 1.7E-09 0.00 4.8E-01 -0.01 1.2E-01 
rs73158393 
NC_000022.10:g.33335386C>G 
SYN3 22q12.3 C/G 0.74 1.06 1.04-1.09 1.1E-06 1.09 1.03-1.14 1.4E-03 1.07 1.05-1.09 7.7E-09 -0.00 7.7E-01 -0.01 3.3E-01 
CI, confidence interval; OR, odds ratio; ICGC, International COPD Genetics Consortium; HGVS, Human Genome Variation Society. This table 
shows association statistics in UK Biobank (21,081 cases and 179,711 controls), ICGC cohorts (14,654 cases and 42,365 controls), the overall meta-
analysis (35,735 cases and 222,076 controls), and SpiroMeta studies (FEV1 and FEV1/FVC; n=79,055). P values are two-sided based on Wald 
statistics (COPD) and t statistics (FEV1 and FEV1/FVC) without multiple comparison adjustment.  White = Significant in SpiroMeta using 
Bonferroni correction for novel loci (one-sided P < 0.05/35); Grey = Nominally significant in SpiroMeta (one-sided P < 0.05), Dark grey = not 
significant (directionally consistent only)
  
URLs 
HGNC database of human gene names, https://www.genenames.org/; The Drug Repurposing 
Hub, https://clue.io/repurposing; The Query, https://clue.io/query; Human Genome Region MHC 
by Genome Reference Consortium, 
https://www.ncbi.nlm.nih.gov/grc/human/regions/MHC?asm=GRCh37.p13; EMBL-EBI GWAS 
Catalog, https://www.ebi.ac.uk/gwas/; LungMAP, https://www.lungmap.net/. 
Methods 
Study populations 
The UK Biobank is a population-based cohort consisting of 502,682 individuals8. To determine 
lung function, we used measures of forced expiratory volume in 1 second (FEV1) and forced 
vital capacity (FVC) derived from the spirometry blow volume-time series data, subjected to 
additional quality control based on ATS/ERS criteria110 (Supplementary Note). As in our 
previous study5, we defined COPD using pre-bronchodilator spirometry according to modified 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate to very 
severe airflow limitation9: FEV1 less than 80% of predicted value (using reference equations 
from Hankinson et al.111), and the ratio between FEV1 and FVC less than 0.7. Consistent with 
our previous analyses and enrollment criteria for COPD case-control datasets112, we did not 
exclude individuals based on self-reported asthma. Genotyping was performed using Axiom UK 
BiLEVE array and Axiom Biobank array (Affymetrix, Santa Clara, California, USA) and 
imputed to the Haplotype Reference Consortium (HRC) version 1.1 panel113.  
We invited participants in the prior International COPD Genetics Consortium (ICGC) COPD 
genome-wide association study to provide case-control association results (with the exception of 
the 1958 British Birth Cohort, to avoid overlapping samples with the replication sample). ICGC 
cohorts performed case-control association analysis based on pre-bronchodilator measurements 
of FEV1 and FEV1/FVC, and cases were identified using modified GOLD criteria, as above. 
Studies were imputed to 1000 Genomes reference panels. Detailed cohort descriptions and 
cohort-specific methods have been previously published5 (Supplementary Note). All studies 
comply to all relevant ethical regulations. Ethical/regulatory boards approved the study protocol 
for each study (Supplementary Note). We obtained informed consent from all participating 
individuals. 
Based on the strong genetic overlap of lung function and COPD5, we performed lookups of 
select significant variants for FEV1 and FEV1/FVC in the SpiroMeta consortium meta-analysis
21. 
Briefly, SpiroMeta comprised a total of 79,055 individuals from 22 studies imputed to either the 
1000 Genomes Project Phase 1 reference panel (13 studies) or the HRC (9 studies). Each study 
performed linear regression adjusting for age, age2, sex, and height, using rank-based inverse 
normal transforms, adjusting for population substructure using principal components or linear 
mixed models, and performing separate analyses for ever- and never- smokers or using a 
covariate for smoking (for studies of related subjects). Genomic control was applied to individual 
studies, and results were combined using a fixed-effects meta-analysis21. 
Genome-wide association analysis 
In UK Biobank, we performed logistic regression of COPD, adjusting for age, sex, genotyping 
array, smoking pack-years, ever smoking status, and principal components of genetic ancestry. 
Association analysis was done using PLINK 2.0 alpha114 (downloaded on December 11, 2017) 
  
with Firth-fallback settings, using Firth regression when quasi-complete separation or regular-
logistic-regression convergence failure occurred. We performed a fixed-effects meta-analysis of 
all ICGC cohorts and UK Biobank using METAL (version 2010-08-01)115. We assessed 
population substructure and cryptic relatedness by linkage disequilibrium (LD) score regression 
intercept10. We defined a genetic locus using a 2-Mb window (+/-1 Mb) around a lead variant, 
with conditional analyses as described below. 
To maximize our power to identify existing and discover new loci, we examined all loci at the 
genome-wide significance value of P < 5 × 10-8. We first characterized loci as being previously 
described (evidence of prior association with lung function12–20,116,117 or COPD5,11,118) or novel. 
We defined previously reported signals if they were in the same LD block in Europeans119 and in 
at least moderate LD (r2 >= 0.2). For novel loci we attempted replication through association of 
each lead variant with either FEV1 or FEV1/FVC ratio in SpiroMeta, using one-sided P-values 
with Bonferroni correction for the number of novel loci examined. Novel loci failing to meet a 
Bonferroni-corrected P-value were assessed for nominal significance (one-sided P < 0.05) or 
directional consistence with FEV1 and FEV1/FVC ratio in SpiroMeta. 
Cigarette smoking is the major environmental risk factor for COPD and genetic loci associated 
with cigarette smoking have been reported5,120. While we adjusted for cigarette smoking in our 
analysis, we further examined these effects by additionally testing for association of each locus 
with cigarette smoking and by looking at two separate analyses of ever- and never- smokers in 
UK Biobank. We tested for sex-specific genetic effects of genome-wide significant variants via a 
stratified analysis and interaction testing, using a 5% Bonferroni-corrected threshold to 
determine significance (Supplementary Note). 
Identification of independent associations at genome-wide significant loci 
We identified specific independent associations at genome-wide significant loci using GCTA-
COJO22. This method utilizes an approximate conditional and joint analysis approach requiring 
summary statistics and representative LD information. As the UK Biobank provided the 
predominant sample, we used 10,000 randomly drawn unrelated individuals from this discovery 
dataset as a LD reference sample. We scaled genome-wide significance to a 2-Mb region, 
resulting in a locus-wide significant threshold of 8 × 10-5, or 2 × 10-6 for variants in the major 
histocompatibility complex (MHC) region (chr6:28477797-33448354 in hg19). We created 
regional association plots via LocusZoom using 1000 Genomes EUR reference data121 (Nov2014 
release).  
Identification and prioritization of tissues and cell types, candidate variants, genes, and 
pathways 
Identification of enriched tissues and specific cell types 
We used LD Score Regression (LDSC) to estimate the enrichment of functional annotations26 
and specifically expressed gene regions31 on disease heritability. We utilized LDSC baseline 
models (e.g., conserved region, promoter flanking region), tissue-specific annotations from the 
Roadmap Epigenomics Program31, integrated tissue annotations from GenoSkyline25, and cell 
type-specific chromatin accessibility data27 (ATAC-Seq). We used four single-cell gene 
expression (RNA-Seq) datasets to identify specific cell types (Supplementary Note), including 
1) lung epithelial cells from normal and pulmonary fibrosis human lung28 (Gene Expression 
Omnibus [GEO] accession GSE86618), 2) human induced pluripotent stem cells (iPSCs)-derived 
putative alveolar type 2 cells29 (GSE96642), 3) mouse lungs at embryonic day 18.5 (E18.5) and 
4) postnatal day 1 (P1) by Whitsett et al. (unpublished, available at LungMAP30). We also used 
  
SNPsea32 to identify enriched cell types in genome-wide significant loci (Supplementary Note). 
We reported only estimates of coefficients and P-values for the Roadmap annotations and gene 
expression datasets, as theses analyses used –h2-cts, which does not report fold enrichment. 
Fine-mapping of independent association signals at genome-wide significant loci 
We used Bayesian fine-mapping at each locus to identify the credible set: the set of variants with 
a 99% probability of containing a causal variant. Briefly, for each genome-wide significant loci 
we calculated approximate Bayes factors33 of association. We then selected variants in each 
locus, so that their cumulative posterior probability was equal or greater than 0.99 using an 
unscaled variance. At loci with multiple independent associations, we used statistics from 
approximate conditional analysis with GCTA software on each index variant adjusting for other 
independent variants in the loci. Otherwise, we used unconditioned statistics from our meta-
analysis. Details on characterization of variant effects are summarized in the Supplementary 
Note.  
Identification of target genes 
We used several computational approaches with corresponding available datasets to identify 
target genes in genome-wide significant loci. We used two methods that utilized gene expression 
data: 1) S-PrediXcan and 2) DEPICT. We used S-PrediXcan37 to identify genes with genetically 
regulated expression associated with COPD. We used data from the Lung-eQTL consortium38 
(1,038 lung tissue samples) as an expression quantitative trait loci (eQTL) and gene expression 
reference database. S-PrediXcan tests for association between a trait and imputed gene 
expression using summary statistics. Here, we performed S-PrediXcan using models for protein-
coding genes +/- 1 Mb from top-associated variants at genome-wide significant loci. We used 
DEPICT (Data-driven Expression Prioritized Integration for Complex Traits)42 to prioritize 
genes from ‘reconstituted’ gene sets. 
We also used additional information on gene regulation, including epigenetic data: 1) regulatory 
fine mapping, 2) methylation quantitative trait loci (mQTL), and 3) chromosome conformation 
capture. We used regulatory fine mapping (regfm41) to overlap 99% credible interval (CI) 
variants at each GWAS locus with open chromatin regions based on DNAse hypersensitivity 
sites (DHS). DHS cluster accessibility state was then associated with gene expression levels (for 
13,771 genes) from 22 tissues in the Roadmap Epigenomics Project41. Using both the 99% CI 
and DHS overlap, as well as the DHS state and transcript level association, regfm calculates a 
posterior probability of association of each gene +/- 1 Mb of the lead SNP at each GWAS locus. 
We also searched for overlapping mQTL data from lung tissue, as recently described39. To 
determine whether these signals co-localized (rather than being related due to linkage 
disequilibrium), we performed colocalization analysis between our GWAS and mQTL in 
genome-wide significant loci using eCAVIAR122 (eQTL and GWAS CAusal Variants 
Identification in Associated Regions, Supplementary Note). We also sought information from 
publicly available chromosome conformation capture data40. We queried association statistics of 
chromatin contact (i.e., long range chromatin interactions) between top associated variants and 
gene promoters nearby in a lung (fetal lung fibroblast cell line (IMR90) and human lung tissue40) 
using HUGIn123 (Hi-C Unifying Genomic Interrogator). We retained only the strongest 
associations (i.e., smallest P-value) for each cell line/primary cell in the analysis.  
Finally, we searched for signals from deleterious variants by querying consequences of variants 
within 99% credible sets containing fewer than 50 variants (Supplementary Note). We also 
searched for rare coding variants, based on exome sequencing results in the COPDGene, Boston 
Early-Onset COPD (BEOCOPD), and International COPD Genetics Network (ICGN) studies, as 
  
previously described43. In brief, we performed exome sequencing on 485 severe COPD cases and 
504 smoking resistant controls from the COPDGene study and 1,554 subjects ascertained 
through 631 probands with severe COPD from the BEOCOPD and the ICGN study. Details on 
statistical tests for single-variant and gene-based analyses are summarized in the Supplementary 
Note.  
For each dataset described above, we used Bonferroni-corrected P-values, or a fixed posterior 
probability threshold to determine target genes at each locus. We reported protein-coding genes 
+/-1 Mb from a top associated variant. We restricted our search to genes from the GRCh37 
server in biomaRt124 with updated HUGO Gene Nomenclature Committee (HGNC) names 
(downloaded from HGNC database of human gene names on June 7, 2018). For each locus, we 
used a 5% Bonferroni-corrected threshold (i.e., P < 0.05 divided by number of genes at that 
locus) to determine significance for 4 data types: gene expression data, chromatin conformation 
capture data, co-regulation of gene expression, and exome sequencing results. For two remaining 
datasets, we used a fixed posterior probability (of gene association with a GWAS locus) 
threshold of 0.1 for regfm and eCAVIAR. We considered genes that were implicated by gene 
expression or >= 2 combination of other datasets (e.g., methylation and chromatin conformation 
capture data) as target genes.  
Identification of pathways 
To identify enriched pathways in COPD-associated loci, we performed gene-set enrichment 
analysis using the “reconstituted” genes sets from DEPICT, as described above42. We defined 
significant gene sets using false discovery rate (FDR) < 5%. 
Effects on COPD-related and other phenotypes 
COPD is a complex and heterogeneous disorder, comprised of different biologic processes and 
specific phenotypic effects. In addition, many loci discovered by GWAS have pleiotropic effects. 
To identify these effects, we performed analyses of a) identification of overlapping genetic loci 
between related disorders (asthma and pulmonary fibrosis) b) genetic association studies of our 
genome-wide significant findings using COPD-related phenotypes, including a cluster analysis 
to identify groups of variants that may be acting via similar mechanisms; c) look up of top 
variants in prior COPD-related quantitative computed tomography (CT) imaging feature GWAS, 
d) look up of associations with other diseases/traits using GWAS Catalog, and e) estimate the 
genetic correlation between COPD and other diseases/traits. 
To identify overlapping loci between COPD and other respiratory disorders, we used gwas-pw53 
to perform pairwise analysis of GWAS. This method searches for shared genomic segments119 
using adaptive significance threshold, allowing detection of sub genome-wide significant loci. 
We identified shared segments or variants using posterior probability of colocalization greater 
than 0.753. We obtained GWAS summary statistics from previous studies of pulmonary fibrosis55 
and asthma in Europeans54. For the overlap analysis of COPD with asthma, we examined the 
influence of the inclusion of individuals with self-reported asthma on both the overlap of discrete 
GWAS loci (using gwas-pw) and genome-wide genetic correlation (using LD score regression) 
by performing these analyses in the meta-analysis of ICGC studies and the UK Biobank (with 
individuals with asthma removed from cases in the latter). To assess heterogeneous effects of 
COPD susceptibility loci on COPD-related features (phenotypes), we evaluated associations of 
our genome-wide significant SNPs with 121 detailed phenotypes (e.g., lung function, computed 
tomography-derived metrics, biomarkers, and comorbidities) available in 6,760 COPDGene non-
Hispanic whites. We calculated Z-scores for each SNP-phenotype combination relative to the 
COPD risk allele to create a SNP by phenotype Z-score matrix. We tested each COPD-related 
  
phenotype with at least one nominally significant association with one of our genome-wide 
significant COPD SNPs, leaving us with 107 phenotypes. We then oriented all Z-scores to be 
positive (based on sign of median Z score) in association with each phenotype to avoid clustering 
based on direction of association. To avoid clustering phenotypes only by strength of association 
with SNPs, we scaled Z-scores within each phenotype by subtracting mean Z-scores and dividing 
by the standard deviation of Z-scores within each phenotype. We then scaled Z-scores across 
SNPs to circumvent clustering of SNPs according only to relative strength of association with 
phenotypes. We then performed hierarchical clustering of the scaled Z-scores of associations 
between SNPs and phenotypes to identify clusters of SNPs and phenotypes for all 107 
phenotypes as well as in the subset of 26 quantitative imaging phenotypes. We performed the 
clustering of variants both in the set of all genome-wide significant variants in discovery as well 
as in the subset of known variants plus novel variants meeting a strict Bonferroni threshold in 
SpiroMeta replication (Supplementary Note). We further examined top variant associations 
with COPD-related traits through a look-up of top variants in a prior GWAS of 12,031 subjects 
with quantitative emphysema and airway CT features50. To examine overlap of our COPD results 
with other traits, we downloaded genome-wide significant associations from the GWAS 
Catalog51 (P < 5 × 10-8; downloaded on April 10, 2018). Between a pair of COPD- and trait- 
associated variants within the same LD block in Europeans119, we computed the LD using the 
European ancestry panel125 and considered the overlap if variants were in at least in moderate LD 
(r2 >= 0.2). We estimated genetic correlation between COPD and other diseases/traits using a 
web engine for LDSC, LD Hub52. We assessed the results using a 5% Bonferroni-corrected 
significance level. 
Identification of drug targets 
We queried our target genes using the Drug Repurposing Hub48. This resource contains 
comprehensive annotations of launched drugs, drugs in phases 1-3 of clinical development, 
previously approved and preclinical or tool compounds, curated using publicly available sources 
(e.g., ChEMBL and Drugbank) and proprietary sources. We performed drug-gene expression 
similarity analysis49 (the Query) using a ranked gene set from a gene-based association test37 
(Supplementary Note). 
Reporting Summary 
We provide further information on research design in the Life Sciences Reporting Summary 
linked to this article. 
Data availability statement 
The genome-wide association summary statistics are available at the database of Genotypes and 
Phenotypes (dbGaP) under accession phs000179.v5.p2 and via the UK Biobank. Derived 
phenotypic data for COPD case control status is also available in the UK Biobank. 
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Editorial summary:  
Genome-wide analysis of chronic obstructive pulmonary disease identifies 82 loci, 35 of which are 
new. Integration of gene expression and genomic annotation data shows enrichment of signals in lung 
tissue, smooth muscle and several lung cell types.  
 
